Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | President, RayzeBio Org. | March 10, 2026 | March 12, 2026 |
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | SVP, Chief Commerical Officer | October 01, 2019 | October 01, 2019 |
| Surface Oncology, Inc.SURF · Entity 109857 | Director | June 08, 2022 | June 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date March 10, 2026 · Filed March 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2029-03-10 | Direct | 11,429 |
Reported balance
After 2026-03-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-10 · Grant · Acquired 11,429 · Balance 11,429 F1: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout. F2: These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2029-03-10 | Direct | 17,143 |
Reported balance
After 2026-03-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-10 · Grant · Acquired 17,143 · Balance 17,143 F3: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board. |
Filing footnotes · ownership attribution and instrument terms
F1: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout.
F2: These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board.
F3: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board.
HALOZYME THERAPEUTICS, INC.
Report date October 01, 2019 · Filed October 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,226 |
Ending reported balance
After 2019-10-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-10-01 · Exercise / conversion · Acquired 20,216 · Balance 20,216 Row 2 · 2019-10-01 · Tax withholding · Disposed 6,990 · Balance 13,226 F1: The reported disposition of 6,990 shares represents the shares that were withheld by the Issuer as payment for minimum statutory tax withholding requirements. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 60,647 |
Reported balance
After 2019-10-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-10-01 · Exercise / conversion · Disposed 20,216 · Balance 60,647 F2: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported disposition of 6,990 shares represents the shares that were withheld by the Issuer as payment for minimum statutory tax withholding requirements.
F2: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the Issuer.
Surface Oncology, Inc.
Report date June 08, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2032-06-08 | Direct | 24,000 |
Reported balance
After 2022-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-08 · Grant · Acquired 24,000 · Balance 24,000 F1: The Options shall vest in twelve equal monthly installments following the date of grant or, if earlier, upon the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: The Options shall vest in twelve equal monthly installments following the date of grant or, if earlier, upon the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mirati Therapeutics, Inc.
Report date January 23, 2024 · Filed January 23, 2024
Section 16 reporting ended · disclosed 2024-01-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-01-23 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-01-23 · Disposition to issuer · Disposed 27,801 · Balance 89,227 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. Row 2 · 2024-01-23 · Disposition to issuer · Disposed 72,206 · Balance 17,021 F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. Row 3 · 2024-01-23 · Disposition to issuer · Disposed 17,021 · Balance 0 F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $45.66 · Expires 2033-01-20 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-23 · Disposition to issuer · Disposed 2,128 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $45.66 · Expires 2033-01-20 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-01-23 · Disposition to issuer · Disposed 43,328 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS.
F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes.
F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU.
F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting.
F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
Mural Oncology plc
Report date December 05, 2025 · Filed December 05, 2025
Section 16 reporting ended · disclosed 2025-12-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.56 · Expires 2035-06-10 | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-05 · Disposition to issuer · Disposed 8,637 · Balance 0 F2: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. F1: This Form 4 reports securities disposed of pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, pursuant to which Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"). The Acquisition was completed as of December 5, 2025 (the "Effective Time"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2034-05-29 | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-05 · Disposition to issuer · Disposed 8,462 · Balance 0 F2: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2033-12-13 | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-05 · Disposition to issuer · Disposed 15,021 · Balance 0 F2: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, pursuant to which Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"). The Acquisition was completed as of December 5, 2025 (the "Effective Time").
F2: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2022 Filed Jan 5, 2022 18:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001209191-22-001906 · doc4.xml · derivative · entry 1 Hickey Benjamin · CIK 0001753055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2032-01-03 F1 · derivative.exercise_date: The options shall vest in 36 equal monthly installments following December 10, 2021, so long as the grantee remains a director or other service provider of the Company on such dates. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 16:42 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionNon Qualified Stock Option (right to buy) · Derivative | 2,369 | $0.00 Strike: $114.33 | $0.00 |
DisclosureSEC source: 0001214659-21-003327 · marketforms-52052.xml · derivative · entry 5 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,116 Underlying: Common Stock · 2,369 shares Expires 2030-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020 F5 · derivative.exercise_date: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 16:42 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 431 | $177.71 | $76,591.11 |
DisclosureSEC source: 0001214659-21-003327 · marketforms-52052.xml · nonDerivative · entry 4 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,812 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020 F4 · price: This transaction was executed in multiple trades at prices ranging from $177.29 to $178.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 16:42 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 1,350 | $176.42 | $238,170.92 |
DisclosureSEC source: 0001214659-21-003327 · marketforms-52052.xml · nonDerivative · entry 3 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,243 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020 F3 · price: This transaction was executed in multiple trades at prices ranging from $176.048 to $177.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 16:42 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 588 | $175.54 | $103,215.58 |
DisclosureSEC source: 0001214659-21-003327 · marketforms-52052.xml · nonDerivative · entry 2 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,593 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020 F2 · price: This transaction was executed in multiple trades at prices ranging from $175.04 to $176.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 16:42 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 2,369 | $114.33 | $270,847.77 |
DisclosureSEC source: 0001214659-21-003327 · marketforms-52052.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020 Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 18:18 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,979 | $0.00 Strike: $214.47 | $0.00 |
DisclosureSEC source: 0001214659-21-000684 · marketforms-50974.xml · derivative · entry 2 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,979 Underlying: Common Stock · 10,979 shares Expires 2031-01-14 F2 · derivative.exercise_date: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 18:18 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 7,023 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-000684 · marketforms-50974.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,812 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 19:46 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 2,069 | $216.33 | $447,586.77 |
DisclosureSEC source: 0001214659-21-000338 · marketforms-50911.xml · nonDerivative · entry 2 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,789 F1 · kind: Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 6, 2020. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 19:46 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 9 | $215.31 | $1,937.76 |
DisclosureSEC source: 0001214659-21-000338 · marketforms-50911.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,858 F1 · kind: Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 6, 2020. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 21:06 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantEmployee Stock Option (Right to Buy) · Derivative | 32,485 | $0.00 Strike: $114.33 | $0.00 |
DisclosureSEC source: 0001214659-20-000226 · marketforms-47393.xml · derivative · entry 2 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,485 Underlying: Common Stock · 32,485 shares Expires 2030-01-05 F2 · derivative.exercise_date: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 21:06 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 21,867 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-000226 · marketforms-47393.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,867 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested. Read SEC document |
| October 01, 2019 Filed Oct 1, 2019 23:10 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 20,216 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-052329 · a4.xml · derivative · entry 3 Hickey Benjamin · CIK 0001753055 · SVP, Chief Commerical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,647 Underlying: Common Stock · 20,216 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the Issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the Issuer. Read SEC document |
| October 01, 2019 Filed Oct 1, 2019 23:10 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 6,990 | $15.46 | $108,065.40 |
DisclosureSEC source: 0001104659-19-052329 · a4.xml · nonDerivative · entry 2 Hickey Benjamin · CIK 0001753055 · SVP, Chief Commerical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,226 F1 · shares: The reported disposition of 6,990 shares represents the shares that were withheld by the Issuer as payment for minimum statutory tax withholding requirements. Read SEC document |
| October 01, 2019 Filed Oct 1, 2019 23:10 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 20,216 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-052329 · a4.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · SVP, Chief Commerical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:29 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 37,538 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001935 · edgar.xml · derivative · entry 2 Hickey Benjamin · CIK 0001753055 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,538 Underlying: Common Stock · 37,538 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on such date and one-fourth on each anniversary thereafter. F2 · derivative.expiration_date: This award vests one-fourth on such date and one-fourth on each anniversary thereafter. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:29 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOptions to purchase common stock · Derivative | 71,602 | $0.00 Strike: $16.65 | $0.00 |
DisclosureSEC source: 0001179110-19-001935 · edgar.xml · derivative · entry 1 Hickey Benjamin · CIK 0001753055 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,602 Underlying: Common Stock · 71,602 shares Expires 2029-02-12 F1 · derivative.exercise_date: This option vests one-fourth on such date and 1/48 monthly thereafter. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:10 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 80,863 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-012004 · edgar.xml · derivative · entry 2 Hickey Benjamin · CIK 0001753055 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,863 Underlying: Common Stock · 80,863 shares Expires 2028-10-01 F2 · derivative.exercise_date: This award vests one-fourth on such date and one-fourth on each anniversary thereafter. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:10 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOptions to purchase common stock · Derivative | 149,516 | $0.00 Strike: $18.55 | $0.00 |
DisclosureSEC source: 0001179110-18-012004 · edgar.xml · derivative · entry 1 Hickey Benjamin · CIK 0001753055 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,516 Underlying: Common Stock · 149,516 shares Expires 2028-10-01 F1 · derivative.exercise_date: This option vests one-fourth on such date and 1/48 monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.